These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20005515)

  • 41. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
    Younk LM; Uhl L; Davis SN
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):753-63. PubMed ID: 21521130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High density lipoprotein metabolism in man.
    Blum CB; Levy RI; Eisenberg S; Hall M; Goebel RH; Berman M
    J Clin Invest; 1977 Oct; 60(4):795-807. PubMed ID: 197124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
    Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport.
    Duffy D; Rader DJ
    Curr Opin Cardiol; 2005 Jul; 20(4):301-6. PubMed ID: 15956827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys.
    Wallace JM; Schwarz M; Coward P; Houze J; Sawyer JK; Kelley KL; Chai A; Rudel LL
    J Lipid Res; 2005 May; 46(5):1009-16. PubMed ID: 15716581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.
    Bruckert E; Labreuche J; Deplanque D; Touboul PJ; Amarenco P
    J Cardiovasc Pharmacol; 2011 Feb; 57(2):267-72. PubMed ID: 21052016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PPARS, metabolic disease and atherosclerosis.
    Fruchart JC; Staels B; Duriez P
    Pharmacol Res; 2001 Nov; 44(5):345-52. PubMed ID: 11712864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease.
    Brewer HB
    Am J Cardiol; 1999 May; 83(9B):3F-12F. PubMed ID: 10357568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of fibric Acid derivatives in cardiovascular prevention.
    Khoury N; Goldberg AC
    Curr Treat Options Cardiovasc Med; 2011 Aug; 13(4):335-42. PubMed ID: 21544518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio.
    Schultze AE; Alborn WE; Newton RK; Konrad RJ
    J Lipid Res; 2005 Aug; 46(8):1591-5. PubMed ID: 15897610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipid profile, apolipoproteins A-1 and B in owl monkeys (Aotus infulatus) in captivity.
    da Silva WB; Teixeira ALS; Oliveira KG; Gonzaga CN; de Souza AM; Almosny NRP
    J Med Primatol; 2022 Dec; 51(6):367-373. PubMed ID: 35916434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states.
    Chan DC; Watts GF
    Curr Vasc Pharmacol; 2008 Jan; 6(1):67-77. PubMed ID: 18220942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ellagic Acid Suppresses ApoB Secretion and Enhances ApoA-1 Secretion from Human Hepatoma Cells, HepG2.
    Ieda A; Wada M; Moriyasu Y; Okuno Y; Zaima N; Moriyama T
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34202121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.
    Wang W; Blackett P; Khan S; Lee E
    J Lipids; 2017; 2017():8236325. PubMed ID: 28473926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of the radiation dose from administered apolipoprotein tracers in humans.
    Venkatakrishnan V; Fisher WR; Zech LA
    Metabolism; 1997 Oct; 46(10):1231-9. PubMed ID: 9322813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.
    Han L; Shen WJ; Bittner S; Kraemer FB; Azhar S
    Future Cardiol; 2017 May; 13(3):259-278. PubMed ID: 28581332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elevated ApoB/ApoA-Ι ratio is associated with poor outcome in acute ischemic stroke.
    Li Z; Zhang D; Song Z; Cui X; Liu L; Ding Y; Xue J; Zhang X; Ma R; Zhu X; Yue Y
    J Clin Neurosci; 2023 Jan; 107():138-143. PubMed ID: 36402710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
    Robinson JG
    PPAR Res; 2008; 2008():891425. PubMed ID: 18288293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemistory of Fibrates.
    Balendiran GK; Verma M; Perry E
    Curr Chem Biol; 2007 Sep; 1(3):311-316. PubMed ID: 34485047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.